HIFU hemiablation in patients with localized prostate cancer

The aim of the study: was to evaluate oncological and functional results of HIFU hemiablation in patients with localized prostate cancer. Materials and methods. The study was based on comparative evaluation of the results of treating patients with localized prostate cancer with HIFU (complete ablation and hemiablation). Over the period of 2011-2017, 250 patients with localized prostate cancer underwent treatment with high intensity focused ultrasound using the SONOBLATE 500 V5 TCM system in the conditions of the department of surgery of the Clinical Center Zdorovie (Rostov-on-Don). All patients were divided into two groups, depending on the volume of ablation performed. The patients from the f irst group (n=200) underwent HIFU by complete ablation of the prostate; patients from the second group underwent hemiablation. Results. According to the screening, PSA nadir was observed by the third month of the trial (0.8 ng/ml in the first group and 1.4 ng/ml in the second). Biochemical recurrence was diagnosed in 28% of patients after complete ablation and in 20% of patients from the hemiablation group. Histological recurrence was observed in 12% and 10% of patients from the first and the second groups, respectively. According to the data obtained, functional results (IIEF 5 index and IPSS, VAS, QOL scales) were high enough in patients after HIFU hemiablation. Conclusion. HIFU hemiablation is a highly effective method for treating patients with localized prostate cancer, if strict selection criteria are applied. This helps to achieve successful functional and oncological outcomes.